12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aubagio teriflunomide: Phase III data

Top-line data from the open-label, international Phase III TENERE trial in 324 patients showed that once-daily 7 and 14 mg oral teriflunomide each missed the primary endpoint of significantly reducing the risk of treatment failure, defined as the occurrence of a confirmed relapse or permanent treatment discontinuation for any cause, vs. Rebif interferon beta-1a at week 48 (48.6% and 37.8%, respectively, vs. 42.3%, p-values not disclosed). On secondary endpoints, there was...

Read the full 351 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >